The paper found that, while cannabis consumers have higher rates of psychotic experiences than non-consumers, the difference was indeed more pronounced among those with a high genetic predisposition to schizophrenia.
Both the cannabis users and non-users showed similar resting heart rates and blood pressure levels, but the study’s authors are still concerned that even young cannabis consumers have an elevated risk of developing cardiovascular disease.
Teens who frequently see billboard or storefront advertising for recreational cannabis products are more likely to use the drug weekly and to have symptoms of cannabis use disorder, according to new research.
A new trial has directly compared the antidepressant effects of psilocybin with a more classical antidepressant, and found that the two are matched in their mood-altering potential.
According to the study, up to a third of supposedly CBD-dominant cannabis products sold in Massachusetts may not contain any CBD at all.
Drug developers say that R-ketamine could potentially deliver a more targeted action with fewer side effects than its more popular chemical twin.
Blood tests are inherently flawed, research has shown, because they don’t indicate how long the THC has been in the system, the driver’s tolerance, how high they actually are or whether they are impaired at that moment.
Cannabis smokers experience emphysema at higher rates than both non-smokers and tobacco smokers, according to new research from the Ottawa Hospital.
This “small but significant increase” in fatal motor vehicle accidents and fatalities could be curbed by effective regulations and educational campaigns, according to researchers.
Delta-8-THC is growing in popularity across North America. But how is it different to its more famous cousin, Delta-9-THC? What are its effects? And is it, like many are claiming, federally legal in the US?